AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025

CME Available: https://auau.auanet.org/node/42997

At the conclusion of this activity, participants will be able to:

1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral antiandrogens. Furthermore, to recognize high-volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team.

2. Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): The learner will be skilled to diagnose M0 CRPC and be able to educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three oral agents and to educate patients about side-effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease Non-metastatic Castrate-Resistant Prostate Cancer (M0 CRPC): Diagnose M0 CRPC and be able to educate patients about using novel oral antiandrogens added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these novel oral agents and to educate patients about side effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease state.

3. Metastatic Castrate-Resistant Prostate Cancer (M1 CRPC): Describe and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and be able to educate their patients on treatment options and participate in a multidisciplinary team caring for men with this disease state of far-advanced prostate cancer.

4. Describe that advanced prostate cancer is a complex group of disease states with an ever-changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients.

5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents, and novel AR targeted agents emerging in 2025 and beyond.

AUA2025: Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them

CME Available: https://auau.auanet.org/node/43041

At the conclusion of this activity, participants will be able to:

1. Confidently apply updated guidelines to the care of patients with non-muscle-invasive bladder cancer.

2. Risk-stratify patients with non muscle- invasive bladder cancer.

3. Adapt treatment choices depending on risk of disease, including consideration to the availability of bacillus Calmette-Guérin.

4. Counsel and manage patients with bacillus Calmette-Guérin-unresponsive non muscle-invasive bladder cancer, including treatment selection with newly approved agents for BCG-unresponsive disease.

5. Individualize patient surveillance according to risk stratification.

6. Evaluate available urinary bladder cancer biomarkers and where to potentially utilize them in practice to inform management.

ACKNOWLEDGEMENTS

This educational activity is supported by an independent educational grants from:

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

AUA2025: Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer

CME Available: https://auau.auanet.org/node/43069

At the conclusion of this CME activity, participants will be able to:

1. Evaluate recent advances in biomarkers and molecular imaging technologies and their role in improving the accuracy of prostate cancer staging, and treatment monitoring.

2. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.

3. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.

4. Apply the findings of PSMA PET/CT for the best individual therapeutic approach.

5. Identify patients with radiorecurrent organ-confined prostate cancer.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

Blue Earth Diagnostics, Inc.

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care Team

CME Available: https://auau.auanet.org/node/42822

At the conclusion of this CME activity, participants will be able to:

1. Apply the mechanism of action of PARP inhibitors and the rationale for using them in patients with advanced prostate cancer.

2. Recognize the role and importance of genetic testing in patients with mCRPC and the implications of germline mutations on response to therapy.

3. Identify best practices and utilize available guidelines for patients with mCRPC to optimize treatment success and oncologic outcomes.

4. Recognize when to use PARP inhibitors as monotherapy, the rationale and indications for combination therapy, and appropriate treatment sequencing.

5. Successfully counsel patients on the possible adverse events associated with PARP inhibitor therapies alone or in combination.

ACKOWLEDGEMENTS

Support provided by independent educational grants from:

AstraZeneca

Merck & Co., Inc.

Live from AUA2025: Advances in ADT Program

CME Available: https://auau.auanet.org/content/LiveFromAUA2025#group-tabs-node-course-default1

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Pfizer, Inc.

Sumitomo Pharma America, Inc.

At the conclusion of this CME activity, participants will be able to:

1. Employ the latest AUA and NCCN guidelines (Version 1.2025) related to Androgen Deprivation Therapy (ADT) into practice

2. Evaluate clinical outcomes, efficacy, and safety profiles of different types of ADT including oral and parenteral LHRH agonists and GnRH receptor antagonists in different treatment settings.

3. Compare testosterone recovery, treatment efficacy, safety profiles, and patient preferences between different modalities of ADT.

4. Recognize common side effects associated with different types of ADT and its combination therapies as well as strategies to mitigate these adverse effects to improve patient outcomes.

5. Implement a multi-disciplinary approach in managing advanced prostate cancer with ADT.

6. Evaluate the future directions and ongoing research that may impact the use of ADT in clinical practice.

AUA2025: Sexual Medicine Society of North America Meeting

Cohost: Landon Trost, MD

Outline:

Segment #1: What is the Sexual Medicine Society of North America and what unique value does it bring to its members and the broader field of urology.

Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting?

Segment #3: What are the main clinical areas being highlighted at the SMSNA meeting at AUA2025?

Segment #4: What is new or exciting on the horizon in your sub-specialty?

Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the SMSNA meeting at AUA2025?

AUA2025: Society of Urological Robotic Surgeons Meeting

Cohost: Michael D. Stifelman, MD

Outline:

Segment #1: What is the Society of Urological Robotic Surgeons and what unique value does it bring to its members and the broader field of urology.

Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting?

Segment #3: What are the main clinical areas being highlighted at the SURS meeting at AUA2025?

Segment #4: What is new or exciting on the horizon in your sub-specialty?

Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the SURS meeting at AUA2025?

AUA2025: Focal Therapy Society Meeting

Cohost: Rafael Sanchez-Salas, MD

Outline:

Segment #1: What is the Focal Therapy Society and what unique value does it bring to its members and the broader field of urology.

Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting?

Segment #3: What are the main clinical areas being highlighted at the FTS meeting at AUA2025?

Segment #4: What is new or exciting on the horizon in your sub-specialty?

Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the FTS meeting at AUA2025?

Update Series 2025 Lesson 9: Congenitalism: Transitioning Patients with Congenital Urological Anomalies from the Pediatric to the Adult Care Setting

Update Series 2025 Lesson 9: Congenitalism: Transitioning Patients with Congenital Urological Anomalies from the Pediatric to the Adult Care Setting

Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25

AUA2025: Masterclass: Renal Access and Interventions (2025)

Cohost: Rob Sweet, MD, FACS, MAMSE and Thomas Chi, MD, MBA

Tune in to hear straight from the experts about what you can expect from our NEWLY DESIGNED Full Day Hands-on Skills Trainings at AUA2025! In this episode, Drs. Thomas Chi and Robert Sweet discuss Masterclass: Renal Access and Interventions, an all new interactive training offering skills in percutaneous renal access and image-guided renal interventions.

Early Bird deadline for Hands-on Skills trainings has been EXTENDED - ends March 24. Spaces are limited – Register now!